In the aseptic compounding unit, thiamylal sodium is handled as a sterile powder for injection that is reconstituted immediately before induction in small-animal surgical procedures. The powder is transferred by vacuum into vials under laminar flow with residual moisture controlled by Karl Fischer titration according to USP <921>; batches are released only when the dried powder meets the finished-product test for particulate matter under USP <788>. Reconstitution is performed with a sterile diluent supplied by the marketing authorization holder, typically Water for Injection or a preservative-free isotonic diluent, because the free acid precipitates when the solution pH falls toward the pKa range of the thiobarbiturate. The resulting solution is inspected against black and white backgrounds for visible particles, then drawn into a syringe pump calibrated in 0.1 mL/h increments for slow IV administration. Published veterinary anesthesia formularies describe IV induction doses in the order of 10–20 mg/kg for dogs and cats, with the lower portion of the range applied when alpha-2 agonists or opioids have been pre-administered. The process limit is strict: once reconstituted, the solution should be used within the in-use stability window established by the clinic’s USP <797> compounding risk category; for most low-risk preparations this is no longer than 12 hours at room temperature or 24–72 hours refrigerated when the manufacturer’s data support it. pH drift from carbon dioxide ingress is controlled by drawing solutions with closed-system transfer devices, and the final preparation is never mixed with acidic solutions such as lactated Ringer’s or 5% dextrose beyond the diluent ratio specified, because precipitation of the acid form is an immediate operational failure.

What Limits Direct Oral Capsule and Tablet Compounding for a Thiobarbiturate Sodium Salt?

Thiamylal sodium is not a first-line oral anesthetic because the free acid is poorly absorbed and the molecule undergoes extensive first-pass metabolism; however, veterinary compounders may prepare low-dose capsules or tablets when a specific patient requires a solid oral form and a veterinarian of record has no practical alternative. The API is triturated with anhydrous lactose monohydrate or spray-dried mannitol in geometric dilution ratio 1:10 steps until the target dose per unit is reached in the range 5–50 mg per capsule, depending on body weight and indication. Direct compression is generally avoided because the sodium salt is hygroscopic and can stick to tooling at relative humidity above 40% RH; instead, wet granulation with a binder solution of polyvinylpyrrolidone K30 at 3–5% w/w is used for tablets, after which granules are dried at 35–40°C to final moisture below 2.0% w/w as measured by USP <921>. A disintegrant such as crospovidone is added intragranularly at 2–4% w/w to ensure disintegration within 30 min under the compendial dissolution test; magnesium stearate is limited to 0.5% w/w because higher levels can delay dissolution of the hydrophobic barbiturate. The finished units are tested for weight variation and content uniformity in accordance with USP <905>; because the dose is in the low milligram range, the coefficient of variation after blending should remain below 3.0% for release. Stability of compounded capsules is assigned a beyond-use date under USP <795>; where stability data are absent, the maximum beyond-use date is not more than 180 days for dry oral solids stored in tightly closed, light-resistant containers. Published data on oral bioavailability of thiamylal sodium in veterinary species is limited, so this route remains extra-label and is documented under the applicable extra-label use framework. The operator records the controlled-substance reconciliation in accordance with DEA records requirements, and the batch documentation includes the powder sieve mesh size of 40–60 mesh for screened aggregates and the result of final visual inspection.

Granulation for unit-dose oral powders and sachets is performed in a facility where the API is deagglomerated through a 40-mesh stainless steel screen and mixed with a carrier blend of powdered sucrose and microcrystalline cellulose in a V-blender running at 25 rpm for 20 min. The target final blend uniformity is set so that each sachet contains not less than 90.0% and not more than 110.0% of the labeled amount, tested by high-performance liquid chromatography with ultraviolet detection. Because the sodium salt is moisture-sensitive, the granulation room is held below 30% RH, and the intermediate is packed into aluminum foil sachets with desiccant canisters within 4 h of final blending. The dry powder is intended for constitution in water immediately before administration to small or exotic animals; if a reconstituted oral suspension must be held, the beyond-use date is assigned under USP <795> as not more than 14 days refrigerated in a tight, light-resistant container. Batch records include Karl Fischer moisture results of ≤2.0% w/w and an assay on the top, middle, and bottom thief samples from the blender. For field use, the sachet is reconstituted to a target concentration of 10 mg/mL using a graduated syringe, and the dose is drawn from a homogeneous suspension under continuous stirring. Published data for thiamylal sodium specifically in this oral granular form is limited; therefore no extension beyond the conservative compounding BUD is made. Granulation operators must observe the same controlled-substance handling and destruction documentation as for any Schedule III barbiturate, and the powder must not be handled in a room used for production animal feed additives.

When the API Is Supplied as a Lyophilized Plug: Vacuum Transfer, Headspace Moisture, and Stopper Selection Constraints

Lyophilized vials of thiamylal sodium are filled from a bulk solution that is kept under nitrogen to minimize oxidative degradation. The filler is programmed for a target fill volume per vial in the range 5–20 mL; after filling, the vials are partially stoppered with bromobutyl lyophilization stoppers and loaded onto shelves pre-cooled to -40°C. Primary drying is run below the collapse temperature observed by freeze-drying microscopy; for thiobarbiturate salt formulations the shelf temperature is typically ramped from -30°C to -10°C over 24–48 h while the chamber pressure is held at 50–100 mTorr. The residual moisture after lyophilization is a critical release parameter; the plug is sampled through the stopper with a dry nitrogen-purged device and analyzed by coulometric Karl Fischer titration according to USP <921>, with a target residual moisture below 2.0% w/w. Headspace oxygen is monitored by laser-based headspace analysis and maintained below 5.0% v/v by nitrogen backfill before final stoppering. The container-closure system is tested for integrity by dye ingress or vacuum decay according to the current USP <1207> chapters. The dry powder is hygroscopic; if the stopper is exposed to ambient air for more than 15 min during re-sealing, the batch is quarantined for moisture re-testing. Reconstitution time is specified by the marketing authorization holder as a visual and practical limit: the plug should dissolve within 60 s of adding the sterile diluent with gentle swirling, and any retained material on the stopper or vial wall is recorded as a process deviation. The finished product is tested for bacterial endotoxins using USP <85> and for particulate matter using USP <788>; these data are part of release certification for the injectable designation. These operations fall under aseptic processing requirements in EU GMP Annex 1 and the applicable portions of 21 CFR 211.42 and 21 CFR 211.67.

Medicated Premix Requests and Cross-Contamination Barriers

Thiamylal sodium is not approved for medicated feed premix use in production species; the downstream evaluation of a premix request is therefore an exclusion decision rather than a formulation routine. The reason is both pharmacological and regulatory: the compound produces central nervous system depression and has no defined target animal safety margin in food-producing species, and a withdrawal period cannot be reliably established under current residue testing. Any handling of bulk API for a proposed premix is confined to a dedicated negative-pressure weighing suite with HEPA filtration and a high-efficiency dust collection system to control airborne fine powder. Cross-contamination into adjacent feed additive lines is prevented by disposable polyethylene bin liners, color-coded scoops, and airlock entry. The powder is blended with a carrier such as ground corn cob or lactose monohydrate in a ribbon mixer at 20 rpm for no more than 10 min because longer mixing can cause electrostatic segregation and dust generation. Dust masks fitted with P3 filters and nitrile gloves are required; the room is cleaned with a high-efficiency cyclone and then wiped with deionized water because the sodium salt is water-soluble. The retained samples are stored in a locked controlled-substance cabinet at 20–25°C and ≤40% RH; the batch documents record the mass balance for Schedule III inventory reconciliation. If a premix application is nonetheless requested for an individual non-food animal under a legitimate veterinary order, the compounder treats it as the oral granule route described above, not as an industrial feed premix. Published data for thiamylal sodium in true medicated feed premix carriers is limited, and no performance claim for feed stability is made.

Multi-dose aqueous solutions for high-volume referral procedures require an in-use stability protocol that starts with a refrigerated stock solution at a concentration of either 25 mg/mL or 50 mg/mL, depending on the species and injection pump reservoir. The stock solution is prepared in a biological safety cabinet under ISO class 5 conditions and filtered through a 0.22 µm polyethersulfone membrane using a peristaltic pump at 100 rpm. The filtered solution is aliquoted into sterile amber vials with minimal headspace and stoppered under vacuum; each vial is labeled with the exact preparation time, concentration, and beyond-use date assigned from USP <797> risk category. During use, a closed-system transfer device is used for withdrawal to limit carbon dioxide ingress and pH drop. The solution is inspected visually before each use; turbidity, gas bubbles, or a sulfurous odor triggers immediate discard because these can indicate hydrolysis or oxidative release of sulfur-containing degradation products. The pH is measured with a calibrated microelectrode and must remain in the alkaline range specified by the manufacturer; if the pH drifts below 9.0, precipitation of the free acid becomes a risk. Refrigerated storage at 2–8°C slows hydrolysis, but published stability data for this specific dilution of thiamylal sodium is limited; therefore the clinic adopts the most conservative beyond-use date allowed by its compounding framework. Syringe pump reservoirs are protected from light during infusion, and the residual volume after the procedure is destroyed in the presence of two licensed staff members according to controlled-substance loss documentation.